148 related articles for article (PubMed ID: 10589350)
1. Does partial control of inflammation prevent long-term joint damage? Clinical rationale for combination therapy with multiple disease-modifying antirheumatic drugs.
Pincus T; Breedveld FC; Emery P
Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S2-7. PubMed ID: 10589350
[No Abstract] [Full Text] [Related]
2. Editorial: Immunomodulatory Functions of Fibroblast-like Synoviocytes in Joint Inflammation and Destruction during Rheumatoid Arthritis.
Xu H; Zheng SG; Fox D
Front Immunol; 2020; 11():955. PubMed ID: 32508834
[No Abstract] [Full Text] [Related]
3. Current immunotherapy in rheumatoid arthritis.
Meier FM; Frerix M; Hermann W; Müller-Ladner U
Immunotherapy; 2013 Sep; 5(9):955-74. PubMed ID: 23998731
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment.
Smith MD; Weedon H; Papangelis V; Walker J; Roberts-Thomson PJ; Ahern MJ
Rheumatology (Oxford); 2010 May; 49(5):862-75. PubMed ID: 20147446
[TBL] [Abstract][Full Text] [Related]
5. Synovial tissue analysis in clinical trials.
Bresnihan B; Baeten D; Firestein GS; Fitzgerald OM; Gerlag DM; Haringman JJ; McInnes IB; Reece RJ; Smith MD; Ulfgren AK; Veale DJ; Tak PP;
J Rheumatol; 2005 Dec; 32(12):2481-4. PubMed ID: 16331792
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
[TBL] [Abstract][Full Text] [Related]
7. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials.
Gerlag DM; Tak PP
Best Pract Res Clin Rheumatol; 2008 Apr; 22(2):311-23. PubMed ID: 18455687
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy.
Pincus T; O'Dell JR; Kremer JM
Ann Intern Med; 1999 Nov; 131(10):768-74. PubMed ID: 10577301
[TBL] [Abstract][Full Text] [Related]
9. The needle and the damage done.
Franz JK; Burmester GR
Ann Rheum Dis; 2005 Jun; 64(6):798-800. PubMed ID: 15897300
[No Abstract] [Full Text] [Related]
10. Progression of joint damage despite control of inflammation in rheumatoid arthritis: a role for cartilage damage driven synovial fibroblast activity.
Lafeber FP; Van der Laan WH
Ann Rheum Dis; 2012 Jun; 71(6):793-5. PubMed ID: 22566404
[No Abstract] [Full Text] [Related]
11. Association of clinical, radiological and synovial immunopathological responses to anti-rheumatic treatment in rheumatoid arthritis.
Pettit AR; Weedon H; Ahern M; Zehntner S; Frazer IH; Slavotinek J; Au V; Smith MD; Thomas R
Rheumatology (Oxford); 2001 Nov; 40(11):1243-55. PubMed ID: 11709608
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Celis R; Moll C; Izquierdo E; Marsal S; Sanmartí R; Palacín A; Lora D; de la Cruz J; Pablos JL
Ann Rheum Dis; 2009 May; 68(5):751-6. PubMed ID: 18495732
[TBL] [Abstract][Full Text] [Related]
13. IL-17 as a future therapeutic target for rheumatoid arthritis.
van den Berg WB; Miossec P
Nat Rev Rheumatol; 2009 Oct; 5(10):549-53. PubMed ID: 19798029
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory Effect of a Novel Antirheumatic Drug T-614 on the IL-6-Induced RANKL/OPG, IL-17, and MMP-3 Expression in Synovial Fibroblasts from Rheumatoid Arthritis Patients.
Wei Y; Sun X; Hua M; Tan W; Wang F; Zhang M
Biomed Res Int; 2015; 2015():214683. PubMed ID: 26273599
[TBL] [Abstract][Full Text] [Related]
15. Antifolate/antiproliferative therapy in rheumatoid arthritis.
Cutolo M
Clin Exp Rheumatol; 2005; 23(4):435-7. PubMed ID: 16095109
[No Abstract] [Full Text] [Related]
16. Synovial cellular and molecular markers in rheumatoid arthritis.
Asif Amin M; Fox DA; Ruth JH
Semin Immunopathol; 2017 Jun; 39(4):385-393. PubMed ID: 28497350
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicine for the Treatment of Rheumatoid Arthritis.
Jeong M; Park JH
Mol Pharm; 2021 Feb; 18(2):539-549. PubMed ID: 32502346
[TBL] [Abstract][Full Text] [Related]
18. Overview of combination second-line or disease-modifying antirheumatic drug therapy in rheumatoid arthritis.
Williams HJ
Br J Rheumatol; 1995 Nov; 34 Suppl 2():96-9. PubMed ID: 8535657
[TBL] [Abstract][Full Text] [Related]
19. Rheumatoid arthritis.
Scott DL; Wolfe F; Huizinga TW
Lancet; 2010 Sep; 376(9746):1094-108. PubMed ID: 20870100
[TBL] [Abstract][Full Text] [Related]
20. Sinomenine Inhibits the Progression of Rheumatoid Arthritis by Regulating the Secretion of Inflammatory Cytokines and Monocyte/Macrophage Subsets.
Liu W; Zhang Y; Zhu W; Ma C; Ruan J; Long H; Wang Y
Front Immunol; 2018; 9():2228. PubMed ID: 30319663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
